易明医药：姚劲波6.62亿入主，设3年业绩承诺

Core Viewpoint - The acquisition of Yiming Pharmaceutical by Yao Jinbo, founder of 58.com, has led to a significant increase in the company's stock price, indicating positive market sentiment towards the new leadership and strategic direction [1] Group 1: Acquisition Details - Yao Jinbo's Beijing Fuhai acquired a 23% stake in Yiming Pharmaceutical, amounting to 43.86 million shares, through a share transfer agreement with the former controlling shareholder, Gao Fan [1] - The share transfer price was set at 15.1 yuan per share, representing a 24% premium over the price before the suspension of trading, totaling 662 million yuan [1] - Following the acquisition, Gao Fan retains a 2.59% voting rights stake, while Yao Jinbo will benefit from the company's undistributed profits and cash dividends [1] Group 2: Financial Performance - As of the end of Q1 2025, Yiming Pharmaceutical reported accumulated undistributed profits of 356 million yuan and plans to distribute cash dividends of 18.69 million yuan for the fiscal year 2024 [1] - The company has performance commitments for the years 2025-2027, with a target of not less than 30 million yuan in net profit attributable to shareholders and a minimum revenue of 600 million yuan [1] - For 2024, Yiming Pharmaceutical anticipates total revenue of 652 million yuan, a year-on-year decrease of 2.27%, while net profit attributable to shareholders is expected to be 46 million yuan, nearly doubling year-on-year [1] Group 3: Business Focus - Yiming Pharmaceutical's product portfolio includes treatments for cardiovascular diseases and diabetes, with its Miglitol tablets winning bids in 25 provinces [1] - The company's management indicated that the previous year's profit growth was due to the absence of goodwill impairment and the development of asset products, with plans to deepen its focus on chronic disease management to enhance performance [1]